Abstract
Background: Mutations in the gene encoding AT- Rich Interactive Domain-containing protein 1A (ARID1A) occur in several cancer types with varying frequency. The predictive impact of ARID1A mutations on platinum-based chemotherapy and immunotherapy have been investigated retrospectively, yielding conflicting results. We report our analysis on the predictive impact of ARID1A status – mutated (MUT) versus (vs.) wild type (WT) – in metastatic solid tumor patients who were exposed to platinum-based chemotherapy and immunotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
